AI & ML · Sep 8
Rentosertib’s Olink data and six aging clocks put AI drug claims on trial
Phase IIa proteomic data gave Insilico’s AI-designed IPF candidate the kind of multi-model check that hype decks tend to forget.
- Treat the rentosertib result as a biological signal, not a cure claim.
- Look for AI drug evidence that links clinical data, biomarkers, and independent model checks.
- Watch Phase III progress to see whether biomarker alignment survives harder clinical testing.